A solid oral dosage form, which is typically a tablet or capsule, comprising: a core material comprising the isomer, isomer, or a mixture of and isomers of -2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile, -2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile, or a mixture of and isomers of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (Compound) having the structure: where *C is a stereochemical center; and/or a pharmaceutically acceptable salt thereof; an enteric coating; a subcoat below the enteric coating, wherein the subcoat: is a water soluble or hydrophilic erodible polymer, said polymer being a low molecular weight polymer selected from hydroxymethyl cellulose (HPMC), hydroxyethyl cellulose, hydroxypropyl cellulose, microcrystalline cellulose, polyvinylpyrrolidones, polysaccharides, a polysaccharide derivative, polyvinyl alcohols, polyethylene glycol, polypropylene glycol, and a PEG-PPG block copolymer; or comprises a water insoluble composition comprising: (i) particles of a water soluble compound capable of forming channels in the water insoluble composition; or (ii) water insoluble hydrophilic particles which cause swelling of the subcoat when in contact with an aqueous media; and a pharmaceutically acceptable excipient, wherein the solid oral dosage form has an onset of release of Compound and/or the pharmaceutically acceptable salt thereof in the jejuno-ileum portion of the intestine of a mammal after administration; and wherein the solid oral dosage form releases at least 80% of Compound and/or the pharmaceutically acceptable salt thereof in 120 minutes in a dissolution vessel comprising an aqueous solution at a pH from 6.4 to 7.4. a core material comprising the isomer, isomer, or a mixture of and isomers of -2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile, -2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile, or a mixture of and isomers of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (Compound) having the structure: where *C is a stereochemical center; and/or a pharmaceutically acceptable salt thereof; where *C is a stereochemical center; and/or a pharmaceutically acceptable salt thereof; an enteric coating; a subcoat below the enteric coating, wherein the subcoat: is a water soluble or hydrophilic erodible polymer, said polymer being a low molecular weight polymer selected from hydroxymethyl cellulose (HPMC), hydroxyethyl cellulose, hydroxypropyl cellulose, microcrystalline cellulose, polyvinylpyrrolidones, polysaccharides, a polysaccharide derivative, polyvinyl alcohols, polyethylene glycol, polypropylene glycol, and a PEG-PPG block copolymer; or comprises a water insoluble composition comprising: (i) particles of a water soluble compound capable of forming channels in the water insoluble composition; or (ii) water insoluble hydrophilic particles which cause swelling of the subcoat when in contact with an aqueous media; and is a water soluble or hydrophilic erodible polymer, said polymer being a low molecular weight polymer selected from hydroxymethyl cellulose (HPMC), hydroxyethyl cellulose, hydroxypropyl cellulose, microcrystalline cellulose, polyvinylpyrrolidones, polysaccharides, a polysaccharide derivative, polyvinyl alcohols, polyethylene glycol, polypropylene glycol, and a PEG-PPG block copolymer; or comprises a water insoluble composition comprising: (i) particles of a water soluble compound capable of forming channels in the water insoluble composition; or (ii) water insoluble hydrophilic particles which cause swelling of the subcoat when in contact with an aqueous media; and a pharmaceutically acceptable excipient, wherein the solid oral dosage form has an onset of release of Compound and/or the pharmaceutically acceptable salt thereof in the jejuno-ileum portion of the intestine of a mammal after administration; and wherein the solid oral dosage form releases at least 80% of Compound and/or the pharmaceutically acceptable salt thereof in 120 minutes in a dissolution vessel comprising an aqueous solution at a pH from 6.4 to 7.4.